Meropenem Sun (Meropenem Anhydrous)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, blocking the cross‑linking of peptidoglycan strands. This leads to weakened cell walls, osmotic instability and ultimately bacterial lysis, providing broad‑spectrum activity against many Gram‑negative, Gram‑positive and anaerobic organisms.

The dosage of Meropenem Sun is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function and other clinical factors. No fixed regimen is provided here; the prescriber sets the appropriate dose and infusion rate.

Safety data for Meropenem during pregnancy and lactation are limited. The drug should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Meropenem Sun, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Meropenem belongs to the carbapenem class, offering a broader spectrum and greater β‑lactamase stability than most penicillins or cephalosporins. Compared with other carbapenems such as imipenem, meropenem has a lower risk of seizures and does not require co‑administration of a renal protective agent, making it a preferred option for many severe infections.

Meropenem Sun must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect from light, and avoid freezing or shaking. Once reconstituted, use the solution promptly according to the product’s stability guidelines.

Meropenem Sun is supplied as a sterile powder for injection. It is reconstituted with the appropriate diluent and administered intravenously, typically as a short infusion over 15–30 minutes. Administration should be performed by qualified healthcare personnel following aseptic technique.

Serious adverse events include seizures (especially in patients with renal impairment or CNS disorders), severe hypersensitivity reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Prompt recognition and medical intervention are essential if any of these events occur.

Meropenem Sun is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving drugs that may interact significantly with meropenem.